Chd5 is a novel tumor suppressor gene
AssigneeCold Spring Harbor Laboratory
InventorsAlea A. Mills, Anindya Bagchi, Cristian Constantin Papazoglu-Statescu
Life of this patent
Estimating the term…
Abstract
The invention provides methods of treating cancer using a Chd5 protein or an agonist thereof. Also provided are diagnostics, screening methods of cancer therapeutics, and cancer models useful for studying cancer biology and drug screening.
Claims33
A method of inhibiting growth of a mammalian cell, comprising increasing the level of a Chd5 protein within the cell.
A method of inducing apoptosis of a mammalian cell, comprising increasing the level of a Chd5 protein within the cell.
A method of inducing expression of p16Ink4a, p19Arf, or p53 in a mammalian cell, comprising increasing the level of a Chd5 protein within the cell.
A method of increasing growth of a mammalian cell, comprising reducing the Chd5 level in the cell.
A method of diagnosing cancer in a human subject, comprising:
- providing a DNA sample from a tissue of the patient, and
- detecting, in said DNA sample, deletion of (1) a nucleic acid sequence in a Chd5 gene, or (2) a nucleic acid sequence flanking the Chd5 gene in the D4Mit190-D4Mit51 interval in chromosome region 1p36, wherein said deletion indicates that the patient has, or is susceptible of developing, cancer in said tissue.
A method of diagnosing cancer in a human patient, comprising:
- providing a tissue sample from the patient,
- determining the level of a Chd5 protein in said tissue sample,
- comparing said level of said Chd5 protein in the patient sample with a level of said Chd5 protein in a control sample, wherein a lower level of said Chd5 protein in said patient sample as compared to the control sample is indicative of the presence of cancer or susceptibility to cancer.
A mouse some or all of whose cells comprise a genome comprising an inactivating mutation in a Chd5 gene.
A mammalian cell whose genome comprises an inactivating mutation in a Chd5 gene.
A mouse some or all of whose cells comprise a genome comprising a coding sequence for an antisense or interfering RNA against a Chd5 transcript.
A mammalian cell whose genome comprises a coding sequence for an antisense or interfering RNA against a Chd5 transcript.
A method of identifying an anti-cancer compound, comprising:
- providing a mammalian cell,
- contacting the cell with a candidate compound,
- determining the level of Chd5 expression in the contacted cell,
- wherein an increased level of Chd5 expression in the contacted cell as compared to a control cell indicates that the candidate compound has an anti-cancer effect.
Dependencies are inferred from the claim text.